Use of Antialergic Medicines: Application of the DDD Methodology in Real Practice

Abstract

Currently, the increase in the number of allergic diseases is considered as a global problem in many countries, including Kyrgyzstan. According to WHO data, allergic diseases are currently ranked 4th among the major chronic diseases in the world. Pharmacotherapy occupies an important place in the treatment of allergy symptoms. To study the use of antiallergic drugs, namely antihistamine and glucocorticoid drugs in real practice, we used the DDD methodology. The aim of the study: to study the use of antiallergic drugs in real practice in the Kyrgyz Republic using the DDD methodology. Materials and research methods. The materials of the study were the data of the Department of Medicines and Medical Devices under the Ministry of Health of the Kyrgyz Republic on the registration of pharmaceutical products in the Kyrgyz Republic, price lists and invoices of wholesale pharmaceutical companies and retail pharmacies in Bishkek. Research results. At the time of the study, the pharmaceutical market of the Kyrgyz Republic has a balanced range of drugs, including 184 trade names of the above groups of drugs, namely 98 antihistamines and 86 glucocorticosteroids. The calculation of the degree of consumption of antiallergic drugs was presented as the number of established daily doses — the number of DDD (NDDD) sold in 2021. Conclusion. Analysis of the obtained data showed that the first place in terms of volume of consumption in natural terms among glucocorticosteroids are drugs containing dexamethasone — 4077 DDD, the second place is occupied by betamethasone — 953 DDD and the third fluticasone — 641 DDD. The leaders in terms of antihistamines consumption were Diphenhydramine — 15320 DDD, Fexofenadine — 3100 DDD and Loratadine — 683 DDD.